Baxter International 公司
BAX
25.28
-0.48
-1.86%
Baxter International 公司
US · BAX
#1293 按市值排名
上市于 2015
25.28
-0.48
-1.86%
实时 - 追踪5344个代码 - 心跳于532秒前
· 2026-10-16 19:30
✦ 量化股权信号 计算方式说明
增持
- 最近一期（2026/Q3）披露持股的机构数量减少了3家。
- 机构持股总比例上升了0.1个百分点。
机构持股
- 机构持股比例
- 110.02% +0.12pp
- 机构数量
- 818 -3
- 数据截至
- 2026/Q3 较上一报告期
持股变动 vs 资金流向
方向分歧机构在上一报告期增持了股份，同时该股在最近20个交易日的主力资金呈净流出——两者方向出现分歧。
机构持股变动数据按季度发布且存在滞后；资金流向数据为每日更新。请将其作为方向性的交叉验证参考，而非精确的择时信号。
持股人类型
Mutual Fund98.95%
Hedge Fund3.22%
Public Company3.12%
Private Company2.39%
Government Pension Fund1.07%
Sovereign Wealth Fund0.80%
Individual/Insider0.42%
Insurance Company0.18%
Family Office/Trust0.17%
主要股东 截至 2026-06-30
BlackRock
15.83% · 81.84M 股
Pzena Investment Management, Inc.
12.63% · 65.30M 股
Dodge & Cox
11.29% · 58.39M 股
Vanguard Capital Management, LLC
7.09% · 36.65M 股
FMR
6.75% · 34.90M 股
Vanguard Portfolio Management, LLC
4.65% · 24.06M 股
State Street Global Advisors
3.98% · 20.60M 股
Strategic Advisers LLC
3.68% · 19.01M 股
Greenhaven Associates Inc
2.76% · 14.29M 股
Geode Capital Management, LLC
2.73% · 14.12M 股
条形长度是相对于此处列出的最大股东而言，并非相对于公司100%股权。
内部人持股
共追踪50份申报 · 24次买入 · 16次卖出
| 姓名 | 职务 | 持股比例 |
|---|---|---|
| Jose Almeida | Chairperson & CEO | 0.11% |
| Jeanne Mason | ?Executive VP & Chief Human Resources Officer | 0.04% |
| Heather Knight | Executive VP & Group President of Medical Products and Therapies | 0.03% |
| Reazur Rasul | Executive VP & Group President of Healthcare Systems and Technologies | 0.02% |
| Christopher Toth | Executive VP & Group President of Kidney Care | 0.02% |
| David Rosenbloom | Executive Vice President | 0.02% |
| Maria Soriano | -- | 0.01% |
| Joel Grade | Chief Financial Officer | 0.01% |
| David Shafer | Lead Independent Director | 0.01% |
| Andrew Hider | Chief Executive Officer | 0.01% |
内部人交易 最近的 Form 4 申报记录
| 日期 | 姓名 | 职务 | 类型 | 股数 | 价格 |
|---|---|---|---|---|---|
| 2026-09-30 | John Rogers | Chief Financial Officer | Initial Statement of Beneficial | 0 | -- |
| 2026-09-14 | Bernie Heine | Interim Chief Accounting Officer & Controller | Initial Statement of Beneficial | 0 | -- |
| 2026-09-01 | Andrew Hider | Chief Executive Officer | Sale to Issuer | -54,276 | $25.70 |
| 2026-09-01 | Julie Foster | President of Front Line Care | Sale to Issuer | -2,098 | $25.70 |
| 2026-08-31 | James Teaff | President of Care & Connectivity Solutions | Sale to Issuer | -750 | $25.48 |
| 2026-06-01 | Steven Wallace | President of Advanced Surgery | Sale to Issuer | -153 | $18.68 |
| 2026-06-01 | James Teaff | President of Care & Connectivity Solutions | Sale to Issuer | -321 | $18.68 |
| 2026-05-31 | Anita Zielinski | Chief Accounting Officer | Other Acquisition | +13,426 | -- |
| 2026-05-04 | Michael McDonnell | Director | Other Acquisition | +12,836 | -- |
| 2026-05-04 | Amy McBride-Wendell | Independent Director | Other Acquisition | +12,836 | -- |
| 2026-05-04 | Patricia Morrison | Independent Director | Other Acquisition | +12,836 | -- |
| 2026-05-04 | Nancy Schlichting | Independent Director | Other Acquisition | +12,836 | -- |
| 2026-05-04 | David Shafer | Lead Independent Director | Other Acquisition | +12,836 | -- |
| 2026-05-04 | Jeffrey Craig | Director | Other Acquisition | +12,836 | -- |
| 2026-05-04 | David Wilkes | Independent Director | Other Acquisition | +12,836 | -- |
| 2026-05-04 | William Ampofo | Director | Other Acquisition | +12,836 | -- |
| 2026-03-31 | Steven Wallace | President of Advanced Surgery | Initial Statement of Beneficial | 0 | -- |
| 2026-03-31 | Julie Foster | President of Front Line Care | Initial Statement of Beneficial | 0 | -- |
| 2026-03-31 | James Teaff | President of Care & Connectivity Solutions | Initial Statement of Beneficial | 0 | -- |
| 2026-03-05 | Joel Grade | Chief Financial Officer | Sale to Issuer | -8,153 | $17.69 |
Form 4 申报记录，每家公司显示最新的一批。"Other Derivative Acquisition"（其他衍生品获取）类目多为限制性股票/期权归属，并非公开市场买入——具体类型见"类型"列。
报价时间 2026-10-16 19:30:05 · 仅供参考，不构成投资建议，也未考虑您的具体情况。
Baxter International 公司 讨论区 0 条评论